GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of
the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients
with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2
treatment.